The results of a three-year pivotal Phase 3 placebo-controlled trial evaluating denosumab in the treatment of bone loss in men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer, showed positive top-line results.
Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, the essential regulator of osteoclasts (the cells that break down bone).
Amgen is studying denosumab in numerous tumor types across the spectrum of cancer induced bone disease.
Such were the findings recently reported by Amgen, Inc –maker of the bone loss drug denosumab.
In this study of more than 1,400 men, denosumab treatment …read more